ASCO 2025 Highlights: What You Need to Know

The ASCO 2025 Annual Meeting has concluded, and our team at HealthDay is bringing you the top research breakthroughs, clinical updates and practice-changing findings unveiled in Chicago (and online).

From immunotherapy advances in gastric cancer to the surprising role of exercise in post-chemo colon cancer survival, our curated coverage offers health care professionals a clear lens into what mattered — and what’s next.

Watch our conference summary below and navigate some curated stories coming out of the conference to explore how the science is shifting, what’s entering practice, and how you might leverage the insights for patient care.

Advances in Cancer Research Described in 15th Cancer Progress Report

2025 ASCO Annual Meeting Summary Featuring Eric Winer, MD, Director of the Yale Cancer Center and Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute

Sponsored by Novartis Pharmaceuticals Corporation

See What’s Possible with SCEMBLIX® (asciminib) Tablets
Novartis continually strives to improve the lives of patients and reduce access barriers to its medications. With 96-week clinical trial data available, clinicians have more to consider when evaluating whether SCEMBLIX aligns with their patients’ treatment goals. Also, access to SCEMBLIX has improved on two fronts: payer coverage and patient affordability. The three largest PBMs currently cover SCEMBLIX, and 77% of SCEMBLIX claims resulted in $0 out-of-pocket for patients* (reflects use of the $0 Co-Pay Plus offer).

*Data on file. NPS analysis of IQVIA Scemblix OOP landscape readout (full year 2023)

Learn more about SCEMBLIX, the 96-week data, and explore local payer coverage here.